Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28168212 | 0.84 | — | — | |
| SCHEMBL23421623 | 0.84 | MAPT (0.32) | MAPTCYP1A2 | |
| SCHEMBL8357 | 0.82 | — | — | |
| SCHEMBL23170 | 0.82 | — | — | |
| SCHEMBL2030154 | 0.82 | — | — | |
| SCHEMBL29039860 | 0.82 | MAPT (0.31) | MAPT | |
| SCHEMBL29039861 | 0.82 | MAPT (0.31) | MAPT | |
| SCHEMBL643272 | 0.80 | — | — | |
| SCHEMBL1810025 | 0.80 | — | — | |
| SCHEMBL6592973 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112220768-A | Preparation method of miglitol tablets | 四川维奥制药有限公司 | 2021-01-15 | — | — | CN | disclosed |
| EP-1801087-B1 | CIS-1,2-SUBSTITUTED STILBENE DERIVATIVES FOR TREATING AND/OR PREVENTING DIABETES | INST RADIATION MED AMMS PLA (CN) | 2012-08-29 | — | — | EP | disclosed |
| US-8039513-B2 | Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes | INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) | 2011-10-18 | — | — | US | disclosed |
| US-20090161561-A1 | Method and system for determining characters of channels | HUAWEI TECHNOLOGIES CO., LTD | 2009-06-25 | — | — | US | disclosed |
| US-20090076114-A1 | Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes | INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) | 2009-03-19 | — | — | US | disclosed |
| EP-1801087-A1 | CIS-1,2-SUBSTITUTED STILBENE DERIVATES AND THE USE THEREROF FOR MANUFACTURING MEDICAMENTS FOR TREATING MEDICAMENTS FOR TREATING AND/OR PREVENTING DIABETES | Institute of Radiation Medicine, Academy of Military Medical Sciences Pla (CN) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076114-A1 | Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes | SLC5A1, SLC5A2, SLC2A1 | MAPT 2930/4885CYP1A2 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.